(Q38378490)

English

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

scientific article published on 06 September 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jan H M Schellens

15

object named as

Jan H M Schellens

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

author name string

Suzanne Leijen

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Robin M J M van Geel

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Anna C Pavlick

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Raoul Tibes

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Lee Rosen

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Albiruni R Abdul Razak

6

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Raymond Lam

7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Tim Demuth

8

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Shelonitda Rose

9

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Mark A Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Tomoko Freshwater

11

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Stuart Shumway

12

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Li Wen Liang

13

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Amit M Oza

14

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Geoffrey I Shapiro

16

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

language of work or name

0 references

publication date

6 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

4371-4380

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The wee1 protein kinase is required for radiation-induced mitotic delay

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fission yeast p107wee1 mitotic inhibitor is a tyrosine/serine kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cdc2 regulatory factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

G2 checkpoint abrogators as anticancer drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-finding in phase I clinical trials based on toxicity probability intervals.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WEE1 inhibition and genomic instability in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Wee1 kinase as a target for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

1 reference

https://pubmed.ncbi.nlm.nih.gov/27601554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2016.67.5991

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38378490&oldid=2143569972"